EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potential Target Line, FGFR3, EGFR and Immune Checkpoint Axis for Bladder Cancer Therapy

Akshayaa Manikandan, Charles Emmanuel Jebaraj Walter, Sankari Durairajan, Natarajan Kumaresan, Anandan Balakrishnan, Ashwini Saravanan, Jezra Emmanuel Walter, Thanka Johnson

Immuno · 25.05.2026 · 6 (2) · 36

DOI: 10.3390/immuno6020036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno, online erschienen am 25.05.2026. Verfasst von Akshayaa Manikandan und 7 weiteren Autor:innen. Die Arbeit nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer worldwide has seen a sharp rise, making it a significant global health concern. Recurrence monitoring is the main concern in treating the disease, and drug resistance follows suit. Treatment options include first-line medications, adjuvant therapy with BCG (Bacillus Calmette–Guérin) instillations, and combination therapies targeting the PD-1/PD-L1 axis. It has varying 5-year relative survival rates depending on the stage at diagnosis. Despite initial treatment success, resistance often develops, leading to relapse. Resistant to standard treatment is often due to immune landscape changes that are controlled by the most aberrant genes in bladder cancer, which also have a hold in the immune environment of the bladder. Dysregulation of FGFR3 (Fibroblast Growth Factor Receptor 3) in bladder cancer contributes to cell proliferation and metastasis. Simultaneously, the alterations in EGFR (Epidermal Growth Factor Receptor) regulation are linked to cell migration and resistance to treatment. FGFR3 in non-muscle invasive bladder cancer and EGFR in muscle-invasive bladder cancer are central elements in triggering various signaling pathways that contribute to chemoresistance. Concentrating the roles of both genes within the bladder tumour, they present opportunities not only as therapeutic targets but also as potential points of resistance and monitoring for recurrence. Exploring FGFR3 and EGFR to enhance treatment efficacy when combined with ICIs and developing markers into reliable diagnostic tools for recurrence, ultimately aiming for improved patient well-being, is the key aspect we propose to target from this narrative.

Zitieren

APA

Manikandan, A., Walter, C. E. J., Durairajan, S., Kumaresan, N., Balakrishnan, A., Saravanan, A., Walter, J. E., & Johnson, T. (2026). Potential Target Line, FGFR3, EGFR and Immune Checkpoint Axis for Bladder Cancer Therapy. Immuno, 6(2), 36. https://doi.org/10.3390/immuno6020036

Vancouver

Manikandan A, Walter CEJ, Durairajan S, Kumaresan N, Balakrishnan A, Saravanan A, et al. Potential Target Line, FGFR3, EGFR and Immune Checkpoint Axis for Bladder Cancer Therapy. Immuno. 2026;6(2):36. doi:10.3390/immuno6020036

BibTeX
@article{Manikandan2026,
  author = {Manikandan, Akshayaa and Walter, Charles Emmanuel Jebaraj and Durairajan, Sankari and Kumaresan, Natarajan and Balakrishnan, Anandan and Saravanan, Ashwini and Walter, Jezra Emmanuel and Johnson, Thanka},
  title = {Potential Target Line, FGFR3, EGFR and Immune Checkpoint Axis for Bladder Cancer Therapy},
  journal = {Immuno},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {36},
  doi = {10.3390/immuno6020036}
}
Kostenlos starten →